Biomarkers of disease activity in multiple sclerosis

Jerome J. Graber, Suhayl Dhib-Jalbut

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

As therapeutic options for multiple sclerosis widen, validated biomarkers of clinical disease activity are urgently needed. Reliable biomarkers would assist in choosing initial therapy, monitoring response to therapy, detecting subclinical disease activity, predicting and possibly preventing therapeutic failure, and hopefully improving both short (relapses) and long-term (disability) outcomes. The presence of oligoclonal bands in the cerebrospinal fluid is a well-validated biomarker that is useful in initial diagnosis. Neutralizing antibodies to interferon-beta are also useful in identifying treatment failure and possibly guiding changes in therapy. The discovery of antibodies to aquaporin-4 in patients with neuromyelitis optica delineates patients with a fundamentally different underlying pathophysiology and clinical course who may require alternate therapeutic approaches. While numerous other candidate biomarkers in serum and cerebrospinal fluid have been described, none so far have the validated reliability necessary for widespread clinical use. The availability of multiple genetic and protein microarray technology may assist in identifying more reliable candidate biomarkers or patterns of multiple biomarkers and improve specificity. The heterogeneity of multiple sclerosis may necessitate individualized biomarkers and therapeutic decisions within distinct subsets of patients.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalJournal of the Neurological Sciences
Volume305
Issue number1-2
DOIs
StatePublished - Jun 15 2011
Externally publishedYes

Fingerprint

Multiple Sclerosis
Biomarkers
Therapeutics
Cerebrospinal Fluid
Aquaporin 4
Oligoclonal Bands
Neuromyelitis Optica
Protein Array Analysis
Interferon-beta
Neutralizing Antibodies
Treatment Failure
Technology
Recurrence
Antibodies
Serum

Keywords

  • Biomarker
  • Cytokine
  • Disease activity
  • Glatiramer
  • Interferon
  • Interleukin
  • Multiple sclerosis
  • T cell

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Biomarkers of disease activity in multiple sclerosis. / Graber, Jerome J.; Dhib-Jalbut, Suhayl.

In: Journal of the Neurological Sciences, Vol. 305, No. 1-2, 15.06.2011, p. 1-10.

Research output: Contribution to journalArticle

Graber, Jerome J. ; Dhib-Jalbut, Suhayl. / Biomarkers of disease activity in multiple sclerosis. In: Journal of the Neurological Sciences. 2011 ; Vol. 305, No. 1-2. pp. 1-10.
@article{4fc08d0d4a8a480d9b5a57e39abcf1b6,
title = "Biomarkers of disease activity in multiple sclerosis",
abstract = "As therapeutic options for multiple sclerosis widen, validated biomarkers of clinical disease activity are urgently needed. Reliable biomarkers would assist in choosing initial therapy, monitoring response to therapy, detecting subclinical disease activity, predicting and possibly preventing therapeutic failure, and hopefully improving both short (relapses) and long-term (disability) outcomes. The presence of oligoclonal bands in the cerebrospinal fluid is a well-validated biomarker that is useful in initial diagnosis. Neutralizing antibodies to interferon-beta are also useful in identifying treatment failure and possibly guiding changes in therapy. The discovery of antibodies to aquaporin-4 in patients with neuromyelitis optica delineates patients with a fundamentally different underlying pathophysiology and clinical course who may require alternate therapeutic approaches. While numerous other candidate biomarkers in serum and cerebrospinal fluid have been described, none so far have the validated reliability necessary for widespread clinical use. The availability of multiple genetic and protein microarray technology may assist in identifying more reliable candidate biomarkers or patterns of multiple biomarkers and improve specificity. The heterogeneity of multiple sclerosis may necessitate individualized biomarkers and therapeutic decisions within distinct subsets of patients.",
keywords = "Biomarker, Cytokine, Disease activity, Glatiramer, Interferon, Interleukin, Multiple sclerosis, T cell",
author = "Graber, {Jerome J.} and Suhayl Dhib-Jalbut",
year = "2011",
month = "6",
day = "15",
doi = "10.1016/j.jns.2011.03.026",
language = "English (US)",
volume = "305",
pages = "1--10",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Biomarkers of disease activity in multiple sclerosis

AU - Graber, Jerome J.

AU - Dhib-Jalbut, Suhayl

PY - 2011/6/15

Y1 - 2011/6/15

N2 - As therapeutic options for multiple sclerosis widen, validated biomarkers of clinical disease activity are urgently needed. Reliable biomarkers would assist in choosing initial therapy, monitoring response to therapy, detecting subclinical disease activity, predicting and possibly preventing therapeutic failure, and hopefully improving both short (relapses) and long-term (disability) outcomes. The presence of oligoclonal bands in the cerebrospinal fluid is a well-validated biomarker that is useful in initial diagnosis. Neutralizing antibodies to interferon-beta are also useful in identifying treatment failure and possibly guiding changes in therapy. The discovery of antibodies to aquaporin-4 in patients with neuromyelitis optica delineates patients with a fundamentally different underlying pathophysiology and clinical course who may require alternate therapeutic approaches. While numerous other candidate biomarkers in serum and cerebrospinal fluid have been described, none so far have the validated reliability necessary for widespread clinical use. The availability of multiple genetic and protein microarray technology may assist in identifying more reliable candidate biomarkers or patterns of multiple biomarkers and improve specificity. The heterogeneity of multiple sclerosis may necessitate individualized biomarkers and therapeutic decisions within distinct subsets of patients.

AB - As therapeutic options for multiple sclerosis widen, validated biomarkers of clinical disease activity are urgently needed. Reliable biomarkers would assist in choosing initial therapy, monitoring response to therapy, detecting subclinical disease activity, predicting and possibly preventing therapeutic failure, and hopefully improving both short (relapses) and long-term (disability) outcomes. The presence of oligoclonal bands in the cerebrospinal fluid is a well-validated biomarker that is useful in initial diagnosis. Neutralizing antibodies to interferon-beta are also useful in identifying treatment failure and possibly guiding changes in therapy. The discovery of antibodies to aquaporin-4 in patients with neuromyelitis optica delineates patients with a fundamentally different underlying pathophysiology and clinical course who may require alternate therapeutic approaches. While numerous other candidate biomarkers in serum and cerebrospinal fluid have been described, none so far have the validated reliability necessary for widespread clinical use. The availability of multiple genetic and protein microarray technology may assist in identifying more reliable candidate biomarkers or patterns of multiple biomarkers and improve specificity. The heterogeneity of multiple sclerosis may necessitate individualized biomarkers and therapeutic decisions within distinct subsets of patients.

KW - Biomarker

KW - Cytokine

KW - Disease activity

KW - Glatiramer

KW - Interferon

KW - Interleukin

KW - Multiple sclerosis

KW - T cell

UR - http://www.scopus.com/inward/record.url?scp=79955678019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955678019&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2011.03.026

DO - 10.1016/j.jns.2011.03.026

M3 - Article

C2 - 21463872

AN - SCOPUS:79955678019

VL - 305

SP - 1

EP - 10

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1-2

ER -